
Peggy Gandia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4495441/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0149321.	3.2	1
2	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. Journal of Viral Hepatitis, 2021, 28, 431-435.	2.0	7
3	Maraviroc exposure is influenced by exogenous thyrotoxicosis. Aids, 2021, 35, 701-703.	2.2	0
4	Neglecting Plasma Protein Binding in COVIDâ€19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure. Clinical Pharmacology and Therapeutics, 2021, 109, 1030-1033.	4.7	9
5	Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?. Clinical Pharmacokinetics, 2020, 59, 1-5.	3.5	12
6	Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach. Fundamental and Clinical Pharmacology, 2020, 34, 279-287.	1.9	8
7	Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2020, 59, 283-285.	3.5	1
8	Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?― Clinical Pharmacokinetics, 2020, 59, 277-279.	3.5	0
9	Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach. Scientific Reports, 2020, 10, 12265.	3.3	7
10	Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study. Journal of Translational Medicine, 2020, 18, 213.	4.4	6
11	Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 1353-1354.	3.5	6
12	HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy. Aids, 2019, 33, 593-594.	2.2	3
13	Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 979-980.	3.5	0
14	Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 973-975.	3.5	2
15	Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 967-968.	3.5	2
16	Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 961-963.	3.5	0
17	Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Fran§aise de Pharmacologie et) Tj ETQq1 1	0.784314	rgBT/Overla
18	Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?. Clinical Pharmacokinetics, 2019, 58, 827-833.	3.5	34

Peggy Gandia

#	Article	IF	CITATIONS
19	Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods. Clinica Chimica Acta, 2018, 479, 56-65.	1.1	13
20	Isavuconazole Kinetic Exploration for Clinical Practice. Drugs in R and D, 2018, 18, 317-321.	2.2	6
21	Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 479-484.	2.5	2
22	Le syndrome d'hyperémèse au cannabisÂ: les éléments du diagnostic dans un service d'accueil de urgences. Toxicologie Analytique Et Clinique, 2017, 29, 337-342.	^S 0.1	2
23	Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?. Fundamental and Clinical Pharmacology, 2017, 31, 245-253.	1.9	3
24	Quinine unbound concentration is the best marker for therapeutic drug monitoring. Therapie, 2016, 71, 487-489.	1.0	1
25	Determination of Plasma Unbound Fraction of Voriconazole in Patients Treated With a Prophylactic or a Curative Treatment. Therapeutic Drug Monitoring, 2014, 36, 752-758.	2.0	9
26	Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. Annals of Transplantation, 2014, 19, 76-81.	0.9	8
27	Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?. Cancer Chemotherapy and Pharmacology, 2013, 71, 531-536.	2.3	27
28	Long-term Prospective Population PK Study in GIST Patients—Letter. Clinical Cancer Research, 2013, 19, 949-949.	7.0	9
29	Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC–MS/MS assay and ultrafiltration method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 907, 94-100.	2.3	32
30	Circuitous diagnosis in concealed self-poisoning with <i>Nerium oleander</i> *. Clinical Toxicology, 2012, 50, 228-229.	1.9	9
31	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. Pharmacological Research, 2011, 63, 432-438.	7.1	21
32	Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacological Research, 2011, 63, 423-431.	7.1	44
33	In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete. Toxicology in Vitro, 2011, 25, 485-491.	2.4	17
34	Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer. Current Clinical Pharmacology, 2011, 6, 274-279.	0.6	4
35	The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine. Fundamental and Clinical Pharmacology, 2011, 25, 104-114.	1.9	5
36	Quantification of topotecan by liquid chromatography–mass spectrometry (LC–MS). Application to intestinal transport using rat everted gut sacs. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 645-652.	2.3	16

Peggy Gandia

#	Article	IF	CITATIONS
37	Influence of pre-analytical conditions on plasma ribavirin concentrations. Arzneimittelforschung, 2010, 60, 636-639.	0.4	2
38	Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome. International Immunopharmacology, 2009, 9, 1131-1136.	3.8	16
39	Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. Therapeutic Drug Monitoring, 2009, 31, 451-456.	2.0	7
40	Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundamental and Clinical Pharmacology, 2008, 22, 189-201.	1.9	23
41	Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrology Dialysis Transplantation, 2008, 23, 3720-3726.	0.7	23
42	Is Once-Daily Mesalazine Equivalent to the Currently Used Twice-Daily Regimen? A Study Performed in 30 Healthy Volunteers. Journal of Clinical Pharmacology, 2007, 47, 334-342.	2.0	18
43	A Bioavailability Study Comparing Two Oral Formulations Containing Zinc (Zn Bis-Glycinate vs. Zn) Tj ETQq1 1 0.7 for Vitamin and Nutrition Research, 2007, 77, 243-248.	784314 rg 1.5	BT /Overlock 10
44	Influence of Simulated Weightlessness on the Intramuscular and Oral Pharmacokinetics of Promethazine in 12 Human Volunteers. Journal of Clinical Pharmacology, 2006, 46, 1008-1016.	2.0	19
45	The influence of weightlessness on pharmacokinetics. Fundamental and Clinical Pharmacology, 2005, 19, 625-636.	1.9	28
46	The Perfused Everted Intestinal Segment of Rat. Arzneimittelforschung, 2004, 54, 467-473.	0.4	6
47	Influence of simulated weightlessness on the pharmacokinetics of acetaminophen administered by the oral route: a study in the rat. Fundamental and Clinical Pharmacology, 2004, 18, 57-64.	1.9	11
48	Cryptorchidism: Incidence, Risk Factors, and Potential Role of Environment; An Update. Journal of Andrology, 2003, 24, 155-162.	2.0	89
49	Influence of Simulated Weightlessness on the Oral Pharmacokinetics of Acetaminophen as a Gastric Emptying Probe in Man: A Plasma and a Saliva Study. Journal of Clinical Pharmacology, 2003, 43, 1235-1243.	2.0	32